help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2006-0539
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilson, H.
Right arrow Articles by Thissen, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilson, H.
Right arrow Articles by Thissen, J. P.
Endocrinology Vol. 148, No. 1 452-460
Copyright © 2007 by The Endocrine Society

Myostatin Gene Deletion Prevents Glucocorticoid-Induced Muscle Atrophy

H. Gilson, O. Schakman, L. Combaret, P. Lause, L. Grobet, D. Attaix, J. M. Ketelslegers and J. P. Thissen

Unité de Diabétologie et Nutrition (H.G., O.S., P.L., J.M.K., J.P.T.), Université Catholique de Louvain, B-1200 Brussels, Belgium; Unité d’Embryologie, Faculté de Médecine Vétérinaire (L.G.), Université de Liège, B-4000 Liège, Belgium; and Human Nutrition Unit (L.C., D.A.), Human Nutrition Research Centre of Clermont-Ferrand, Unité Mixte de Recherche 1019 Institut National de la Recherche Agronomique, 63122 Ceyrat, France

Address all correspondence and requests for reprints to: Jean-Paul Thissen, Unité de Diabétologie et Nutrition, Université Catholique de Louvain, 54 avenue Hippocrate, B-1200 Brussels, Belgium. E-mail: thissen{at}diab.ucl.ac.be.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Glucocorticoids mediate muscle atrophy in many catabolic states. Myostatin expression, a negative regulator of muscle growth, is increased by glucocorticoids and myostatin overexpression is associated with lower muscle mass. This suggests that myostatin is required for the catabolic effects of glucocorticoids. We therefore investigated whether myostatin gene disruption could prevent muscle atrophy caused by glucocorticoids. Male myostatin knockout (KO) and wild-type mice were subjected to dexamethasone treatment (1 mg/kg·d for 10 d or 5 mg/kg·d for 4 d). In wild-type mice, daily administration of low-dose dexamethasone for 10 d resulted in muscle atrophy (tibialis anterior: –15%; gastrocnemius: –13%; P < 0.01) due to 15% decrease in the muscle fiber cross-sectional area (1621 ± 31 vs. 1918 ± 64 µm2, P < 0.01). In KO mice, there was no reduction of muscle mass nor fiber cross-sectional area after dexamethasone treatment. Muscle atrophy after 4 d of high-dose dexamethasone was associated with increased mRNA of enzymes involved in proteolytic pathways (atrogin-1, muscle ring finger 1, and cathepsin L) and increased chymotrypsin-like proteasomal activity. In contrast, the mRNA of these enzymes and the proteasomal activity were not significantly affected by dexamethasone in KO mice. Muscle IGF-I mRNA was paradoxically decreased in KO mice (–35%, P < 0.05); this was associated with a potentially compensatory increase of IGF-II expression in both saline and dexamethasone-treated KO mice (2-fold, P < 0.01). In conclusion, our results show that myostatin deletion prevents muscle atrophy in glucocorticoid-treated mice, by blunting the glucocorticoid-induced enhanced proteolysis, and suggest an important role of myostatin in muscle atrophy caused by glucocorticoids.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
CATABOLIC CONDITIONS ARE associated with hypercortisolism, which in turn plays a major role in skeletal muscle atrophy (1, 2). Indeed, administration of high doses of glucocorticoids induces muscle atrophy, mainly due to the stimulation of muscle proteolysis (3, 4). This glucocorticoid-induced protein degradation is mainly mediated by the activation of the ubiquitin-proteasome and lysosomal pathways. In particular, the muscle-specific E3-ligases, atrogin-1 and muscle ring finger 1 (MuRF1), and the lysosomal enzyme cathepsin L are highly stimulated by glucocorticoids (1, 5, 6). Furthermore, the inhibition of glucocorticoid action by RU486, an antagonist of the glucocorticoid receptor, markedly reduces the loss of muscle mass encountered in several catabolic states (2, 7).

Myostatin, a member of the TGF-ß family, is an important negative regulator of skeletal muscle mass (8). Indeed, targeted disruption of myostatin gene expression in mice leads to dramatic increases in skeletal muscle mass due to muscle fiber hyperplasia and/or hypertrophy (8, 9). In addition, natural inactivating mutations of the myostatin gene in cattle are associated with a double-muscling phenotype (10, 11, 12). Conversely, transgenic mice that overexpress myostatin selectively in skeletal muscle have lower muscle mass (13). All together, these observations indicate that muscle myostatin regulates negatively the skeletal muscle mass.

Dexamethasone-induced muscle atrophy is associated with a dose-dependent marked induction of muscle myostatin mRNA and protein expression (14). Increased muscle myostatin expression has been also reported in several models of muscle atrophy such as immobilization, microgravity, and burn injuries, in which glucocorticoids play a major role (15, 16, 17). These observations indirectly suggest that myostatin may play a crucial role in glucocorticoid-induced muscle loss. However, it is not yet directly established whether the presence of myostatin is required for the expression of the glucocorticoid-induced catabolic effects. Moreover, the potential role of myostatin in the glucocorticoid activation of the components of the ubiquitin-proteasome and lysosomal proteolytic pathways is still unknown.

We therefore investigated whether myostatin gene disruption could prevent muscle atrophy caused by glucocorticoids and whether this protective effect may result from down-regulation of the ubiquitin-proteasome and lysosomal pathways.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
Eight-week-old male myostatin knockout (KO) FVB mice harboring a constitutive deletion of the third myostatin exon (n = 28 KO mice) (9) and 8-wk-old wild-type (WT) male FVB mice (n = 28 WT mice) provided by Janvier Breeding (Le-Genest-Saint-Isle, France) were used to assess the role of myostatin in the muscle atrophy caused by glucocorticoids. The animals were housed individually under controlled conditions of lighting (12-h light, 12-h dark cycle) and temperature (22 ± 2 C). All animals were allowed to free access to chow and water. Body weight was measured daily. The study was conducted in accordance with the directives of the Institutional Animal Care and Use Committee of the University of Louvain.

Experimental design
After 1 wk adaptation to environment and diet, KO as well as WT mice were randomly allocated to one of four treatment groups. Two groups were injected with dexamethasone, whereas the two others were injected with saline. The saline groups received a daily sc injection of saline solution (vehicle, 0.9% NaCl). The glucocorticoid-treated groups received a daily sc injection of saline solution of dexamethasone (Aacidexam; Organon, Oss, The Netherlands), at either 1 mg/kg·d (low dose) or 5 mg/kg·d (high dose). Mice injected with the high and low dose and their corresponding control groups were killed by decapitation, respectively, after 4 and 10 d of dexamethasone treatment. For biochemical analysis, gastrocnemius muscles were removed, weighted, deep frozen in liquid nitrogen, and stored at –80 C until further analysis. For histological analysis, tibialis anterior muscles were dissected, weighed, and a transversal slice of 0.5 cm thickness was made in the middle belly of the muscle. This slice was embedded in Tissue Tek (Sakura, Zoeterwoude, The Netherlands), frozen in precooled isopentane, and stored at –80 C until further analyzed. The morphological analyses and protein measurements were performed on samples collected at d 10 and the biochemical analyses were obtained from muscles collected at d 4.

Muscle protein extraction
Briefly, 100 mg of whole gastrocnemius muscle, previously pestled in liquid nitrogen, were homogenized with Ultraturrax (IKA-Labortechnik, Staufen, Germany) in 1 ml ice-cold lysis buffer [50 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonylfluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 mM ß-glycerophosphate, 1 mM KH2PO4, 1 mM vanadate, 50 mM NaF, 10 mM NaPPi]. Homogenates were centrifuged 10 min at 10,000 rpm (Sorvall SS-34 rotor) to pellet myofibrillar proteins. Myofibrillar proteins, resuspended in 8 M urea per 50 mM Tris/HCl (pH 7.5), were stored at –80 C as well as the supernatant containing the soluble proteins. Myofibrillar and soluble muscle protein concentrations were determined using Bradford’s protein assay (Bio-Rad, Munich, Germany).

Peptidase activities of the 20S proteasome
Proteolytic activities of the 20S proteasome were measured on individual gastrocnemius muscles collected after 4 d of treatment with dexamethasone 5 mg/kg·d, as previously described (18). One hundred milligrams of skeletal muscles from WT and KO mice treated or not with dexamethasone were homogenized in ice-cold buffer (pH 7.5) containing 50 mM Tris, 250 mM sucrose, 10 mM ATP, 5 mM MgCl2, 1 mM dithiothreitol (DTT), and protease inhibitors (10 µg/ml antipain, aprotinin, leupeptin, and pepstatin A and 20 µM phenylmethylsulfonyl fluoride). The proteasomes were isolated by three sequential centrifugations. The final pellet was resuspended in buffer containing 50 mM Tris (pH 7.5), 5 mM MgCl2, and 20% glycerol. The protein content of the proteasome preparation was determined according to Lowry et al. (42). Peptidase activities of the proteasome were determined by measuring the hydrolysis of the fluorogenic substrates Succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVY) and Boc-Leu-Arg-Arg-7-amido-4-methylcoumarin (LRR). These substrates are preferentially hydrolyzed by the chymotrypsin-like and the trypsin-like peptidase activities of the proteasome, respectively.

To measure peptidase activity, 15 µl of the proteasome extract were added to 30 µl of preincubation medium containing 50 mM Tris (pH 8.0), 12.5 mM MgCl2, 1.5 mM DTT, 0.012 U/µl apyrase, and ± 66.6 µM MG132 and preincubated 15 min at room temperature to allow complete inhibition of the proteasome. Then 30 µl of the reaction buffer containing 50 mM Tris (pH 8.0), 10 mM MgCl2, 1 mM DTT, 0.008 U/µl apyrase, and 750 µM LLVY or 2 mM LRR were added to the 45 µl of the preincubation reaction so that final concentrations were as follows: 300 µM LLVY-AMC or 800 µM LRR-AMC and 40 µM MG132. The peptidase activity was determined by measuring the accumulation of the fluorogenic cleavage product [methylcoumaryl-amide (MCA)] using a luminescence spectrometer FLX800 (Biotek, Winsookie, VT). Fluorescence was measured continuously during 45 min at 380 nm (MCA) excitation wavelength and 440 nm (MCA) emission wavelength. The difference between arbitrary fluorescence units recorded with or without 40 µM of the proteasome inhibitor MG132 (Affiniti, Golden, CO) in the reaction medium was calculated, and the final data were corrected by the amount of protein in the sample. The time course for the accumulation of MCA after hydrolysis of the substrate was analyzed by linear regression to calculate peptidase activities, e.g. the slopes of best fit of accumulated MCA vs. time. Different kinetics were performed to measure individually the two proteasome peptidase activities.

RNA extraction and analysis by real-time quantitative (RTQ)-PCR
Total RNA was isolated from the gastrocnemius muscle using TRIzol reagent as described by the manufacturer. Recovery was 1 µg/mg gastrocnemius. Reverse transcriptase using 1 µg of total RNA was done as previously described (19). Specific primers were determined using the Primer Express software (Applied Biosystems, Foster City, CA). Accession number for the sequences and primers used were: IGF-I, NM184052 (GCTATGGCTCCAGCATTCG-TCCGGAAGCAACACTCATCC); IGF-II, NM031511 (GTCGATGTTGGTGCTTCTCATCT-CGGTCCGAACAGACAAACTGAA); myostatin, AY204900 (GGCTTGACTGCGATGAG-ATATAGCATATTAATGGGAGACAT); atrogin-1, AF441120 (AGCGACCTCAGCAGTTACTGC-CTTCTGGAATCCAGGATGGC); MuRF1: AF294790 (TGTCTGGAGGTCGTTTCCG-ATGCCGGTCCATGATCACTT); cathepsin L, NM009807 (CTCATGAAGGCTGTGGCGA-AACTGGAGAGACGGATGGCTT); forkhead box class O (FOX) O3a, NM019740 (TCGTCTCTGAACTCCTTGCGT-TGGAGTGTCTGGTTGCCGT); and glyceraldehyde-3-phosphate dehydrogenase, AF106860 (TGCACCACCAACTGCTTA-GGATGCAGGGATGATGTTC) used as reporter gene. Primers were tested to avoid primers dimers, self-priming formation, or unspecific amplification. Primers were designed to have standardized optimal PCR conditions.

RTQ-PCR was carried out using following cycle parameters: 10 min at 95 C, followed by 40 cycles of 1 min at 60 C and 15 sec at 95 C. For each gene, RTQ-PCR was conducted in duplicate with 25 µl reaction volume of 1 ng cDNA. To ensure the quality of the measurements, each plate included for each gene a negative control and a positive control. Results were expressed using the comparative cycle threshold (Ct) method as described in the user bulletin no. 2 (Applied Biosystems). Briefly, the {Delta}Ct values were calculated in every sample for each gene of interest as followed: Ctgene of interest – Ctreporter gene with glyceraldehyde-3-phosphate dehydrogenase as the reporter gene. The calculation of the relative changes in the expression level of one specific gene ({Delta}{Delta}Ct) was performed by subtraction of the {Delta}Ct from the control group to the corresponding {Delta}Ct from the treated groups (19, 20) The values and ranges given in different figures were determined as followed: 2–{Delta}{Delta}Ct with {Delta}{Delta}Ct + SEM and {Delta}{Delta}Ct – SEM, where SEM is the SEM of the {Delta}{Delta}Ct value (user bulletin no. 2; Applied Biosystems).

Histological analysis of muscle
Cryostat serial sections (10 µm thick) were obtained and mounted onto glass slides. The sections were fixed 2 min with acetone for hematoxylin-eosin staining. Muscle and fiber cross-sectional area (CSA) were measured with a microscope (Leitz, Wetzlar, Germany) coupled to an image analyzer system (Kontron image analysis division MOP-Videoplan, Eching, Germany). To evaluate muscle fiber CSA, 200 fibers were randomly chosen and counted per muscle.

Statistical analysis
Results are presented as means ± SEM. Interaction between the glucocorticoids and the absence of myostatin was assessed by using two-way ANOVA followed by a Bonferroni posttest using GraphPad Prism (version 4.00 for Windows; GraphPad Software, San Diego, CA). Fiber CSA distribution statistical analysis was performed using {chi}2 Pearson test. Statistical significance was set at P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Animal weight
Baseline body weights were 6% higher in KO than WT mice (P < 0.01). Body weight remained stable over 10 d in saline-injected WT and KO mice (Fig. 1Go). Dexamethasone administration, at the low dose, caused a progressive decline in body weight of WT mice, which was already significant (P < 0.05) at d 1. At the end of the 10 d of dexamethasone treatment, body weight decreased by 5% vs. baseline (P < 0.05). In contrast, no detectable decrease in body weight was observed in dexamethasone-injected KO mice after 10 d. The high dose of dexamethasone decreased the body weight in both groups, the effect being slightly more pronounced in WT than KO mice (–5.3%, P < 0.01 and –2.7%, P < 0.05 after 4 d, respectively, interaction genotype * treatment: P = 0.08).


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		FIG. 1. Deletion of myostatin gene prevents the body weight loss due to low dose dexamethasone treatment. Evolution of body weight of KO (dotted line) and WT (solid line) mice, treated for 10 d with dexamethasone (1 mg/kg·d, black points) or saline (white points). Results are expressed as mean ± SEM. *, P < 0.05, **, P < 0.01 vs. d 0.

 
Muscle weight
Deletion of myostatin in mice led to excessive muscle growth, as illustrated by a large increase in skeletal muscle mass (tibialis anterior: +62%, P < 0.001; gastrocnemius: +47%, P < 0.001; soleus: +41%, P < 0.001 vs. WT mice) (Fig. 2Go).


Figure 2
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 2. Deletion of myostatin gene prevents the muscle atrophy caused by dexamethasone treatment. WT and KO mice were injected for 10 d with dexamethasone (1 mg/kg·d, black box) or saline (white box). Tibialis anterior (A), gastrocnemius (B), and soleus (C) masses are expressed as mean ± SEM. **, P < 0.01, °°°, P < 0.001 vs. WT mice injected with saline.

 
After 10-d dexamethasone treatment, the tibialis anterior and gastrocnemius muscle weights were significantly lower in WT mice injected with the low dose of dexamethasone, compared with their controls injected with saline (–15 and –13%, respectively, P < 0.01). Soleus muscle weight was not significantly affected by dexamethasone, although the same tendency was observed (–11%, P > 0.05). By contrast, in the KO mice, no reduction of muscle mass was observed after the low-dose dexamethasone treatment (tibialis anterior: +2%, P > 0.05; gastrocnemius: –3%, P > 0.05; soleus: +12%, P > 0.05). The effects of 4 d treatment with the high dose of dexamethasone were similar to those observed after 10 d treatment with the low dose (WT mice: tibialis anterior, –13%, P < 0.01; gastrocnemius, –14%, P < 0.01; soleus, –11%, P > 0.05, and KO mice: tibialis anterior, +5%, P > 0.05; gastrocnemius, –3%, P > 0.05; soleus, +4% P > 0.05) (Fig. 3Go). These data suggest that KO mice are protected against the muscle loss induced by dexamethasone.


Figure 3
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 3. Deletion of myostatin gene prevents the muscle atrophy caused by dexamethasone treatment. WT and KO mice were injected for 4 d with dexamethasone (5 mg/kg·d, black box) or saline (white box). Tibialis anterior (A), gastrocnemius (B), and soleus (C) masses are expressed as mean ± SEM. **, P < 0.01, °°°, P < 0.001 vs. WT mice injected with saline.

 
Muscle fiber CSA
The histomorphological analysis of the tibialis anterior showed that the increased muscle mass observed in the KO mice results from hyperplasia, but no effect on fiber size (hypertrophy) could be detected. Indeed, the total muscle area was largely increased in the KO mice, compared with WT (10.57 ± 0.54 vs. 6.40 ± 0.3 mm2, P < 0.001), whereas the muscle fiber CSA was similar in the two groups (KO: 1878 ± 74 vs. WT: 1918 ± 64 µm2, P > 0.05). As shown in Fig. 4AGo, the muscle loss induced by dexamethasone in the WT mice was due to a decrease of 15% of the mean muscle fiber CSA (1621 ± 31 vs. 1918 ± 64 µm2, P < 0.01). By contrast, dexamethasone treatment did not reduce the muscle fiber CSA in the KO mice (1898 ± 34 vs. 1878 ± 74 µm2, P > 0.05). We also compared the fiber size distribution of the tibialis anterior in WT and KO mice injected with dexamethasone or saline. In the WT mice, dexamethasone clearly increased the proportion of fibers of small size (P < 0.001) (Fig. 4BGo). This was in contrast with the observation that in KO mice fiber size distribution was unaffected by dexamethasone (P > 0.05) (Fig. 4CGo). These results confirm the fact that the invalidation of the myostatin gene prevents the muscle atrophy caused by the dexamethasone treatment.


Figure 4
View larger version (22K):
[in this window]
[in a new window]

  		FIG. 4. Deletion of myostatin gene prevents the muscle fiber atrophy induced by dexamethasone treatment. The fiber CSA (A) was measured on tibialis anterior after 10 d of treatment with dexamethasone (1 mg/kg·d, black box) or saline (white box). Results are expressed as mean ± SEM. **, P < 0.01 vs. WT injected with saline. In WT mice (B), the proportion of large fibers was smaller in dexamethasone-treated mice (1 mg/kg·d, black box) than saline group (white box). By contrast, in KO mice (C), the fiber CSA was similar in dexamethasone- and saline-treated groups. Statistical analysis was performed using {chi}2 Pearson test. ***, P < 0.001.

 
Myofibrillar and soluble muscle proteins
Like the muscle weight, the myofibrillar and soluble protein contents were significantly greater in the KO mice, compared with the WT animals (myofibrillar: 16.3 ± 0.6 vs. 11.6 ± 0.3 mg/muscle, P < 0.001; soluble: 14.2 ± 1.2 vs. 9.0 ± 0.5 mg/muscle, P < 0.001) (Fig. 5AGo). The myofibrillar content was significantly decreased with low-dose dexamethasone in the WT mice (8.9 ± 0.2 vs. 11.6 ± 0.3 mg/muscle, P < 0.01) but not the KO (16.1 ± 0.6 vs. 16.3 ± 0.6 mg/muscle, P > 0.05). The muscle soluble protein content did not decrease significantly with dexamethasone in either of the two groups (WT: 7.5 ± 0.4 vs. 9.0 ± 0.5 mg/muscle, P > 0.05, and KO: 13.3 ± 1.2 vs. 14.2 ± 1.2 mg/muscle, P > 0.05).


Figure 5
View larger version (27K):
[in this window]
[in a new window]

  		FIG. 5. A, Deletion of myostatin gene prevents the decrease in myofibrillar protein content caused by dexamethasone (dexa). The myofibrillar protein contents were determined in gastrocnemius after 10 d of treatment with dexamethasone (1 mg/kg·d, black box) or saline (white box). Data are expressed as mean ± SEM. ***, P < 0.001, °°°, P < 0.001 vs. WT injected with saline. B, Deletion of myostatin gene blunts the induction of muscle cathepsin L, atrogin-1, MuRF1, and FOXO3a mRNA caused by dexamethasone treatment. The mRNA levels were determined in gastrocnemius after 4 d of treatment with dexamethasone (5 mg/kg·d) or saline. Results are expressed as mean ± SEM. *, P < 0.05, **, P < 0.01 vs. WT mice injected with saline.

 
Proteolysis-related gene expression
Glucocorticoids are known to increase the protein degradation in muscle by the activation of the ubiquitin-proteasome and lysosomal proteolytic systems. We therefore investigated in WT and KO mice the expression of atrogin-1, MuRF1, and cathepsin L enzymes involved, respectively, in activation of the ubiquitin-proteasome and lysosomal systems. The mRNA levels of these enzymes were equivalent in saline-injected WT and KO mice, showing that myostatin is not a major regulator of their expression in baseline conditions (Fig. 5BGo). Dexamethasone increased the expression of atrogin-1 (+67%, P < 0.05), MuRF1 (+89%, P < 0.01), and cathepsin L (+42%, P < 0.01) in the gastrocnemius muscle of WT mice. In contrast, the mRNA of these enzymes was not significantly affected by dexamethasone in KO mice (atrogin-1: –14%, P > 0.05; MuRF1: +36%, P > 0.05; cathepsin L: –1%, P > 0.05). Because the expression of atrogin-1 and cathepsin L is up-regulated by the transcription factor FOXO3a, we also evaluated changes in its gene expression in the four experimental groups. Dexamethasone increased significantly the FOXO3a expression in the WT animals (+96%, P < 0.01) but not significantly in the KO mice (+39%, P > 0.05). All together, these data suggest that a lack of response to dexamethasone treatment in several pathways involved in muscle proteolysis is closely associated with absence of myostatin.

Peptidase activities of the 20S proteasome
Proteolytic activities of the 20S proteasome were measured on individual gastrocnemius muscles collected after 4 d of treatment with dexamethasone (5 mg/kg·d), according to the methodology previously described (18). Our results show that dexamethasone treatment increased the chymotrypsin-like activity of the 20S proteasome in WT mice (28.61 ± 1.62 vs. 12.31 ± 1.21 relative fluorescence units (RFU)/min·µg protein, P < 0.001) (Fig. 6AGo). The baseline chymotrypsin-like activity was higher in KO than WT mice (29.69 ± 2.67 vs. 12.31 ± 1.21 RFU/min·µg, P < 0.001). Most importantly, this activity was not stimulated by glucocorticoids in KO mice (25.11 ± 2.11 vs. 29.69 ± 2.67 RFU/min·µg, P > 0.05) supporting the concept that myostatin is mandatory to allow the glucocorticoid-induced stimulation of the proteasome. We also measured the trypsin-like activity of the 20S proteasome but failed to show any difference between KO and WT mice after the dexamethasone treatment (WT: 17.86 ± 1.50 vs. 17.91 ± 1.43 RFU/min·µg, P > 0.05; KO: 20.86 ± 1.13 vs. 17.48 ± 2.05 RFU/min·µg, P > 0.05) (Fig. 6BGo). Combined with the data on atrogin-1 and MuRF1, these results strongly suggest that myostatin gene deletion prevents the glucocorticoid-induced muscle atrophy partially at least by inhibition of the ubiquitin-proteasome system.


Figure 6
View larger version (15K):
[in this window]
[in a new window]

  		FIG. 6. Deletion of myostatin gene prevents the increase of the chymotrypsin-like activity of the proteasome 20S induced by dexamethasone treatment (A). The trypsin-like activity of the proteasome 20S is not affected by dexamethasone treatment in WT and KO mice (B).The proteasomal activities were measured in gastrocnemius after 4 d of injections with dexamethasone (5 mg/kg·d, black box) or saline (white box). Results are expressed as mean ± SEM. ***, P < 0.001, °°°, P < 0.001 vs. WT mice injected with saline.

 
Growth factors and myostatin gene expression
Because IGF-I is known to possess an inhibitory effect on atrogin-1, MuRF1, and cathepsin L gene expression, we investigated the hypothesis that this growth factor could repress the glucocorticoid-induced activation of these enzymes in KO animals. As expected, dexamethasone reduced expression of IGF-I in WT mice (–53%, P < 0.001) (Fig. 7Go). Surprisingly IGF-I mRNA was lower in saline-injected KO mice than WT animals (–35%, P < 0.05). Given the fact that IGF-II is also able to interact with the IGF-RI receptor, we monitored its expression in both groups. The muscle IGF-II expression was not affected by dexamethasone but strongly stimulated by the absence of myostatin (+104% in saline-treated and +79% in dexamethasone-treated KO mice, respectively, P < 0.01).


Figure 7
View larger version (12K):
[in this window]
[in a new window]

  		FIG. 7. Deletion of myostatin gene does not prevent the decrease of IGF-I mRNA (white box) induced by dexamethasone (dexa) but causes an increase of IGF-II mRNA (black box), which is not affected by dexamethasone treatment. mRNA levels were measured in gastrocnemius after 4 d of injections with dexamethasone (5 mg/kg·d) or saline. Results are expressed as mean ± SEM. ***, P < 0.001; °, P < 0.05; °°, P < 0.01; °°°, P < 0.001 vs. WT mice injected with saline.

 
As previously reported, muscle atrophy observed in WT mice treated with dexamethasone was associated with an increased expression of myostatin (+38%, P < 0.05 after 4 d). As expected, myostatin expression was not detected in KO mice.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our observations showed that myostatin gene deletion prevents the skeletal muscle atrophy caused by glucocorticoids. Thus, glucocorticoids administration decreased the muscle weight, muscle fiber CSA, and myofibrillar protein content in control WT mice, whereas these catabolic effects were not observed in myostatin KO mice. To our knowledge, this is the first report of the antiatrophic effect of the absence of myostatin in a model of acquired muscle atrophy. The results suggest that muscle myostatin expression is a major player in the atrophic action of glucocorticoids toward muscle.

Increased proteolysis by the ubiquitin-proteasome and lysosomal systems play a major role in glucocorticoid-induced muscle atrophy (1, 5, 6). Also, recent evidence has been provided that the transcription factor FOXO stimulates the transcription of several components of these systems such as atrogin-1, MuRF1, and cathepsin L and causes muscle atrophy (21, 22). Given the key role of myostatin in the protection of the muscle from the glucocorticoid-induced atrophy, we attempted to evaluate its possible effect as a down-regulator of these atrogenes. Anticipating early responses, we determined the muscle mRNA content of atrogenes at an early stage treatment (4 d treatment) in mice injected with a high dose of dexamethasone. In this model, we confirmed that glucocorticoids in WT mice increased muscle expression of atrogin-1 and MuRF1, the two ubiquitin-ligases crucial for muscle atrophy (1, 23), and cathepsin L, a lysosomal enzyme considered an early marker of muscle atrophy (6, 24). Most importantly, this activation of atrogenes was blunted in the myostatin-disrupted mice, pointing to a key role of this negative growth factor on these two proteolytic pathways. Very recently, using the in vitro approach, McFarlane et al. (25) showed that myostatin increased atrogin mRNA in myotubes. This finding is in agreement with our data demonstrating that myostatin is required for the glucocorticoid-induced activation of this enzyme. The same authors (25) also showed that the effect of myostatin on atrogin is mediated by the activation of FOXO1. In our experiment, we observed that the FOXO3a mRNA is strongly induced by glucocorticoids and that this activation is blunted in KO mice. This suggested that FOXO3a is also involved in the myostatin-mediated changes of atrogin-1. Changes in FOXO3a phosphorylation could not be demonstrated, given the very low expression of the protein in our model.

Early studies have shown that myostatin inhibited protein synthesis (26, 27). Up to now, an effect on proteolysis has never been proved. Examining the chymotrypsin-like activity of the proteasome, we observed a higher level in KO than WT mice, suggesting some increase in protein degradation. Given the massive increase in muscle mass of KO mice, it could be speculated that this increased proteolysis might be overridden by accelerated protein synthesis. Such large changes in proteolysis and protein synthesis may indicate a turnover more characteristic of an extensive remodeling process than normal growth. This hypothesis would required additional experimental demonstration. We further examined the effect of myostatin gene deletion on glucocorticoid-stimulated proteasomal activity. Induction of the chymotrypsin-like activity by glucocorticoids was clearly present in WT mice but was not observed in KO mice. Taken together, our observations showed that the presence of myostatin is mandatory for the induction of the components of the proteolytic pathways and proteasomal activity by glucocorticoids. This concept is directly supported by in vitro data showing that myostatin added directly to myotubes causes their atrophy as well as an induction of components of the proteolytic pathway (25). Some in vivo data also suggest that high myostatin levels in the circulation obtained by transplantation of CHO cells engineered ex vivo with myostatin cDNA (25, 28) or in the muscle by overexpressing myostatin (13, 25) cause some muscle atrophy. Glucocorticoid-induced muscle atrophy may be related to increased myostatin muscle expression, as we observed with others (14). An alternate explanation would be that glucocorticoids also act indirectly by relieving a suppressor of myostatin activity, such as follistatin.

The role of IGFs in the muscle hypertrophy observed in myostatin KO mice has not yet been explored, even though these growth factors possess anabolic and anticatabolic effects (29). Indeed, persistent overexpression of IGF-I in mice results in skeletal muscle hypertrophy (30). Furthermore, localized IGF-I overexpression by gene electrotransfer in vivo prevents also muscle atrophy caused by glucocorticoids (31).

Unexpectedly we observed a slight reduction of muscle IGF-I mRNA levels in control KO vs. control WT mice. This decrease in muscle IGF-I mRNA in myostatin KO mice has also been observed by another group using DNA microarray (32). However, IGF-II mRNA expression was increased in the muscle of myostatin KO mice. This observation is in line of previous publications reporting by other technical approaches (immunohistochemistry and DNA microarray) (32, 33), an increase in IGF-II mRNA in skeletal muscles of myostatin KO animals. Although this up-regulation of IGF-II in myostatin KO might suggest a direct negative effect of myostatin on this gene, no such evidence is yet available. Our observation of an inverse relationship between myostatin and IGF-II expression is in line with the work of Lalani et al. (15) showing that muscle atrophy induced in the rat by exposure to microgravity was associated with an up-regulation of myostatin and a down-regulation of IGF-II without change in IGF-I. The increased IGF-II expression in myostatin KO mice might contribute to the skeletal muscle hypertrophy of these animals. Indeed, it is possible that IGF-II acts through an interaction with the IGF-RI receptor (34). Moreover, in a strain of pigs characterized by a nucleotide substitution in intron 3 of the IGF-II gene, muscle IGF-II mRNA levels are increased 3-fold, and this was associated with increased skeletal muscle mass (35). Persistent overexpression of IGF-II mRNA in dexamethasone-treated KO mice might therefore participate to the antiatrophic effect of the myostatin deletion. It is not excluded that other signaling pathways such as Wnt, recently described to be activated in myostatin KO mice (32), participate to the dexamethasone resistance of these animals.

The results obtained in this experience contrast with those of McMahon et al. (36), who showed that myostatin KO mice lose more skeletal muscle mass than WT during hindlimb suspension. Some hypotheses can be raised to explain the absence of the protective effect of the myostatin deletion in this catabolic situation. First, whereas glucocorticoid-induced atrophy affects mainly fast-twitch muscle fibers (myosin heavy chains IIB) (37), in which myostatin is abundantly expressed (38), muscle atrophy caused by unloading affects mainly slow-twitch muscle fibers (melanin-concentrating hormone I), in which myostatin is less expressed (38). These slow-twitch fibers might be therefore less sensitive than the fast twitch to the protective effects of the inhibition of myostatin, explaining the lack of protective response in the unloading model of muscle atrophy. Second, several data suggest that the glucocorticoid-induced muscle atrophy is mediated through the activation of FOXO (21). We showed that myostatin deletion blunted the FOXO3a gene expression in the dexamethasone-treated mice, consistent with an interaction between myostatin and FOXO regulation. In contrast, hindlimb suspension is thought to be related to the induction of the nuclear factor-{kappa}B (39), and it could be hypothesized that this pathway is independent of myostatin expression.

Rodents treated with exogenous glucocorticoids may have reduced food intake. It is therefore possible that reduction in muscle weight caused by dexamethasone may be related partially to decreased food intake. To exclude this possibility, we assessed in a preliminary experiment the daily food intake in WT FVB 8-wk-old male mice treated with dexamethasone 1 mg/kg·d for 10 d and could not find any reduction. However, because we did not measure food intake in animals exposed to higher doses of dexamethasone, we cannot exclude a contribution of reduced food intake to muscle atrophy in animals treated with 5 mg/kg·d dexamethasone.

Our observation that myostatin deletion protects the muscle from dexamethasone-induced atrophy is obtained in animals in which the negative growth factor was deleted constitutively. It remains unknown, however, whether the inhibition of myostatin in postnatal life retains the potential to inhibit the glucocorticoid-induced muscle atrophy. An answer to this question is mandatory to justify the development of myostatin antagonists. Nevertheless, blockage of endogenous myostatin either by injections of blocking antibodies or postnatal gene excision resulted in an increase in muscle mass and strength in normal (40, 41) and mdx dystrophic mice. These observations suggest that postnatal inhibition of myostatin might also blunt the muscle atrophy caused by glucocorticoids.

In conclusion, we have demonstrated that invalidation of myostatin gene prevents the muscle atrophy caused by dexamethasone. Because glucocorticoids are involved in muscle atrophy observed in many catabolic conditions (1), our data suggest that myostatin inhibition may be a very promising approach and a clinically relevant avenue for the preservation, attenuation, or reversal of disease-related muscle loss.


   Footnotes
 
Disclosure Statement: The authors have nothing to disclose.

First Published Online October 12, 2006

Abbreviations: CSA, Cross-sectional area; Ct, cycle threshold; DTT, dithiothreitol; FOX, forkhead box class O; KO, knockout; LLVY, Succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin; LRR, Boc-Leu-Arg-Arg-7-amido-4-methylcoumarin; MCA, methylcoumaryl-amide; MuRF1, muscle ring finger 1; RFU, relative fluorescence units; RTQ, real-time quantitative; WT, wild type.

Received April 24, 2006.

Accepted for publication October 4, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Hasselgren PO 1999 Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 2:201–205[CrossRef][Medline]
  2. Lang CH, Nystrom GJ, Frost RA 2002 Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. Am J Physiol Regul Integr Comp Physiol 282:R207–R215
  3. Dardevet D, Sornet C, Savary I, Debras E, Patureau-Mirand P, Grizard J 1998 Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging. J Endocrinol 156:83–89[Abstract]
  4. Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K 1999 Preventive effects of insulinlike growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 22:213–217[CrossRef][Medline]
  5. Auclair D, Garrel DR, Chaouki ZA, Ferland LH 1997 Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol 272:C1007–C1016
  6. Komamura K, Shirotani-Ikejima H, Tatsumi R, Tsujita-Kuroda Y, Kitakaze M, Miyatake K, Sunagawa K, Miyata T 2003 Differential gene expression in the rat skeletal and heart muscle in glucocorticoid-induced myopathy: analysis by microarray. Cardiovasc Drugs Ther 17:303–310[CrossRef][Medline]
  7. Konagaya M, Bernard PA, Max SR 1986 Blockade of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU38486, a potent glucocorticoid antagonist. Endocrinology 119:375–380[Abstract/Free Full Text]
  8. McPherron AC, Lawler AM, Lee SJ 1997 Regulation of skeletal muscle mass in mice by a new TGF-ß superfamily member. Nature 387:83–90[CrossRef][Medline]
  9. Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, Christians E, Desmecht D, Coignoul F, Kahn R, Georges M 2003 Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 35:227–238[CrossRef][Medline]
  10. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, Georges M 1997 A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17:71–74[CrossRef][Medline]
  11. Kambadur R, Sharma M, Smith TP, Bass JJ 1997 Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7:910–916[Abstract/Free Full Text]
  12. McPherron AC, Lee SJ 1997 Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94:12457–12461[Abstract/Free Full Text]
  13. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, Fielder TJ, Gonzalez-Cadavid NF 2003 Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 285:E876–E888
  14. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian B 2003 Glucocorticoid-induced skeletal muscle atrophy is associated with upregualtion of myostatin gene expression. Am J Physiol Endocrinol Metab 285:E363–E371
  15. Lalani R, Bhasin S, Byhower F, Tarnuzzer R, Grant M, Shen R, Asa S, Ezzat S, Gonzalez-Cadavid NF 2000 Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol 167:417–428[Abstract]
  16. Kawada S, Tachi C, Ishii N 2001 Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. J Muscle Res Cell Motil 22:627–633[CrossRef][Medline]
  17. Lang CH, Silvis C, Nystrom G, Frost RA 2001 Regulation of myostatin by glucocorticoids after thermal injury. FASEB J 15:NIL323–NIL338
  18. Combaret L, Dardevet D, Rieu I, Pouch MN, Bechet D, Taillandier D, Grizard J, Attaix D 2005 A leucine-supplemented diet restores the defective postprandial inhibition of proteasome-dependent proteolysis in aged rat skeletal muscle. J Physiol 569(Pt 2):489–499
  19. Dehoux MJ, van Beneden RP, Fernandez Celemin L, Lause PL, Thissen JP 2003 Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 544:214–217[CrossRef][Medline]
  20. Winer J, Jung CK, Shackel I, Williams PM 1999 Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41–49[CrossRef][Medline]
  21. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ 2004 The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14:395–403[CrossRef][Medline]
  22. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL 2004 Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412[CrossRef][Medline]
  23. Bodine SC, Latres E, Baumhueter S, Lai VKM, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na EQ, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ 2001 Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708[Abstract/Free Full Text]
  24. Deval D, Mordier S, Obled C, Bechet D, Combaret L, Attaix D, Ferrara M 2001 Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem J 360:143–150[CrossRef][Medline]
  25. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R 2006 Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-{kappa}B-independent, FoxO1-dependent mechanism. J Cell Physiol 209:501–514[CrossRef][Medline]
  26. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard Jr DH, Kull Jr FC, Gonzalez-Cadavid N 2001 Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 280:E221–E228
  27. Welle S, Bhatt K, Pinkert CA 2006 Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab 290:E409–E415
  28. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ 2002 Induction of cachexia in mice by systemically administered myostatin. Science 296:1486–1488[Abstract/Free Full Text]
  29. Glass DJ 2005 Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37:1974–1984[Medline]
  30. Song YH, Godard M, Li Y, Richmond SR, Rosenthal N, Delafontaine P 2005 Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Invest Med 53:135–142[Medline]
  31. Schakman O, Gilson H, de Coninck V, Lause P, Verniers J, Havaux X, Ketelslegers JM, Thissen JP 2005 Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146:1789–1797[Abstract/Free Full Text]
  32. Steelman CA, Recknor JC, Nettleton D, Reecy JM 2006 Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J 20:580–582[Free Full Text]
  33. Kocamis H, Gahr SA, Batelli L, Hubbs AF, Killefer J 2002 IGF-I, IGF-II, and IGF-receptor-1 transcript and IGF-II protein expression in myostatin knockout mice tissues. Muscle Nerve 26:55–63[CrossRef][Medline]
  34. Florini JR, Ewton DZ, Coolican SA 1996 Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 17:481–517[Abstract/Free Full Text]
  35. van Laere AS, Nguyen M, Braunschweig M, Nezer C, Collette C, Moreau L, Archibald AL, Haley CS, Buys N, Tally M, Andersson G, Georges M, Andersson L 2003 A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig. Nature 425:832–836[CrossRef][Medline]
  36. McMahon CD, Popovic L, Oldham JM, Jeanplong F, Smith HK, Kambadur R, Sharma M, Maxwell L, Bass JJ 2003 Myostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspension. Am J Physiol Endocrinol Metab 285:E82–E87
  37. Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, de Bock V, Dom R, Decramer M 1995 Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol 78:629–637[Abstract/Free Full Text]
  38. Carlson CJ, Booth FW, Gordon SE 1999 Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol 277:R601–R606
  39. Hunter RB, Kandarian SC 2004 Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114:1504–1511[CrossRef][Medline]
  40. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS 2002 Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418–421[CrossRef][Medline]
  41. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O’Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM 2003 Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965–971[CrossRef][Medline]
  42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ 1951 Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275[Free Full Text]



This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
L. Carraro, S. Ferraresso, B. Cardazzo, C. Romualdi, C. Montesissa, F. Gottardo, T. Patarnello, M. Castagnaro, and L. Bargelloni
Expression profiling of skeletal muscle in young bulls treated with steroidal growth promoters
Physiol Genomics, July 9, 2009; 38(2): 138 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. J. Tisdale
Mechanisms of Cancer Cachexia
Physiol Rev, April 1, 2009; 89(2): 381 - 410.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. S. Willis, M. Rojas, L. Li, C. H. Selzman, R.-H. Tang, W. E. Stansfield, J. E. Rodriguez, D. J. Glass, and C. Patterson
Muscle ring finger 1 mediates cardiac atrophy in vivo
Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H997 - H1006.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Amirouche, A.-C. Durieux, S. Banzet, N. Koulmann, R. Bonnefoy, C. Mouret, X. Bigard, A. Peinnequin, and D. Freyssenet
Down-Regulation of Akt/Mammalian Target of Rapamycin Signaling Pathway in Response to Myostatin Overexpression in Skeletal Muscle
Endocrinology, January 1, 2009; 150(1): 286 - 294.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. J. Lopez, R. J. Ardecky, B. Bebo, K. Benbatoul, L. De Grandpre, S. Liu, M. D. Leibowitz, K. Marschke, J. Rosen, D. Rungta, et al.
LGD-5552, an Antiinflammatory Glucocorticoid Receptor Ligand with Reduced Side Effects, in Vivo
Endocrinology, May 1, 2008; 149(5): 2080 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
O Schakman, H Gilson, and J P Thissen
Mechanisms of glucocorticoid-induced myopathy
J. Endocrinol., April 1, 2008; 197(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. A. Frost and C. H. Lang
Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass
J Appl Physiol, July 1, 2007; 103(1): 378 - 387.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilson, H.
Right arrow Articles by Thissen, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilson, H.
Right arrow Articles by Thissen, J. P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals